European Archives of Oto-Rhino-Laryngology

, Volume 273, Issue 10, pp 3101–3107 | Cite as

Hearing outcome does not depend on the interval of intratympanic steroid administration in idiopathic sudden sensorineural hearing loss

  • Hideaki SuzukiEmail author
  • Hiroki Koizumi
  • Jun-ichi Ohkubo
  • Nobusuke Hohchi
  • Shoji Ikezaki
  • Takuro Kitamura


We studied the effect of intratympanic steroid administration with different intervals on hearing outcomes in patients with idiopathic sudden sensorineural hearing loss (ISSNHL). The subjects were 197 consecutive patients (197 ears) with ISSNHL (hearing level ≥40 dB, interval between onset and treatment ≤30 days). They received systemic administration of prednisolone (100 mg followed by tapered doses) combined with intratympanic injection of dexamethasone (4 mg/ml). Intratympanic injection was performed once a week for 4 weeks in 105 patients (long-interval group), or 4 times in 1 week in 92 patients (short-interval group). The hearing outcomes were evaluated at two points of time: 1 week from the start of treatment, and 1–2 months after the completion of treatment when the hearing level reached a plateau. There was no significant difference in the cure rate, marked-recovery rate, recovery rate, hearing gain, hearing level, or percent hearing improvement between the long- and short-interval groups at either point of time. Multiple regression analysis also showed that the final hearing level did not depend on the interval of intratympanic steroid injection. These results indicate that the hearing outcome of ISSNHL does not improve even if the interval of intratympanic injection is shortened. This implies that a lower total number of intratympanic steroid injections may be as effective as the present protocol.


Idiopathic sudden sensorineural hearing loss Intratympanic steroid administration Interval Hearing outcome 


Compliance with ethical statndards


The authors have no funding or financial relationships as to this work.

Conflict of interest

The authors have no funding, financial relationships or conflict of interests to disclose.

Ethical approval

All procedures performed in this study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent

Informed consent was not obtained from participants because the study was a retrospective review of patients’ clinical records and the information was anonymized and de-identified prior to analysis.


  1. 1.
    Eisenman D, Arts HA (2000) Effectiveness of treatment for sudden sensorineural hearing loss. Arch Otolaryngol Head Neck Surg 126:1161–1164CrossRefPubMedGoogle Scholar
  2. 2.
    Wilson WR, Byl FM, Laird N (1980) The efficacy of steroids in the treatment of idiopathic sudden hearing loss. a double-blind clinical study. Arch Otolaryngol 106:772–776CrossRefPubMedGoogle Scholar
  3. 3.
    Nosrati-Zarenoe R, Hultcrantz E (2012) Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: randomized triple-blind placebo-controlled trial. Otol Neurotol 33:523–531CrossRefPubMedGoogle Scholar
  4. 4.
    Parnes LS, Sun AH, Freeman DJ (1999) Corticosteroid pharmacokinetics in the inner ear fluids: an animal study followed by clinical application. Laryngoscope 109(Suppl 91):1–17CrossRefPubMedGoogle Scholar
  5. 5.
    Suzuki H, Hashida K, Nguyen KH, Hohchi N, Katoh A, Koizumi H, Ohbuchi T (2012) Efficacy of intratympanic steroid administration on idiopathic sudden sensorineural hearing loss in comparison with hyperbaric oxygen therapy. Laryngoscope 122:1154–1157CrossRefPubMedGoogle Scholar
  6. 6.
    Kanzaki J, Taiji H, Ogawa K (1988) Evaluation of hearing recovery and efficacy of steroid treatment in sudden deafness. Acta Otolaryngol Suppl 456:31–36CrossRefPubMedGoogle Scholar
  7. 7.
    Suzuki H, Furukawa M, Kumagai M, Takahashi E, Matsuura K, Katori Y, Shimomura A, Kobayashi T (2003) Defibrinogenation therapy for idiopathic sudden sensorineural hearing loss in comparison with high-dose steroid therapy. Acta Otolaryngol 123:46–50CrossRefPubMedGoogle Scholar
  8. 8.
    Suzuki H, Tabata T, Koizumi H, Hohchi N, Takeuchi S, Kitamura T, Fujino Y, Ohbuchi T (2014) Prediction of hearing outcomes by multiple regression analysis in patients with idiopathic sudden sensorineural hearing loss. Ann Otol Rhinol Laryngol 123:821–825CrossRefPubMedGoogle Scholar
  9. 9.
    Samuel A, Spear MD, Schwartz SR (2011) Intratympanic steroids for sudden sensorineural hearing loss: a systematic review. Otolaryngol Head Neck Surg 145:534–543CrossRefGoogle Scholar
  10. 10.
    Lavigne P, Lavigne F, Saliba I (2016) Intratympanic corticosteroids injections: a systematic review of literature. Eur Arch Otorhinolaryngol (in press)Google Scholar
  11. 11.
    Battaglia A, Burchette R, Cueva R (2008) Combination therapy (intratympanic dexamethasone + high-dose prednisone taper) for the treatment of idiopathic sudden sensorineural hearing loss. Otol Neurotol 29:453–460CrossRefPubMedGoogle Scholar
  12. 12.
    Ahn JH, Yoo MH, Yoon TH, Chung JW (2008) Can intratympanic dexamethasone added to systemic steroids improve hearing outcome in patients with sudden deafness? Laryngoscope 118:279–282CrossRefPubMedGoogle Scholar
  13. 13.
    Hong SM, Park CH, Lee JH (2009) Hearing outcomes of daily intratympanic dexamethasone alone as a primary treatment modality for ISSHL. Otolaryngol Head Neck Surg 141:579–583CrossRefPubMedGoogle Scholar
  14. 14.
    Rauch SD, Hapin CF, Antonelli PJ, Babu S, Carey JP, Gantz BJ, Goebel JA, Hammerschlag PE, Harris JP, Isaacson B, Lee D, Linstrom CJ, Parnes LS, Shi H, Slattery WH, Telian SA, Vrabec JT, Reda DJ (2011) Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss. JAMA 305:2071–2079CrossRefPubMedGoogle Scholar
  15. 15.
    Filipo R, Attanasio G, Viccaro M, Russo FY, Mancini P, Rocco M, Pietropaoli P, Covelli E (2012) Hyperbaric oxygen therapy with short duration intratympanic steroid therapy for sudden hearing loss. Acta Otolaryngol 132:475–481CrossRefPubMedGoogle Scholar
  16. 16.
    Filipo R, Attanasio G, Russo FY, Viccaro M, Mancini P, Covelli E (2013) Intratympanic steroid therapy in moderate sudden hearing loss: a randomized, triple-blind, placebo-controlled trial. Laryngoscope 123:774–778CrossRefPubMedGoogle Scholar
  17. 17.
    Gundogan O, Pinar E, Imre A, Ozturkcan S, Cokmez O, Yigiter AC (2013) Therapeutic efficacy of the combination of intratympanic methylprednisolone and oral steroid for idiopathic sudden deafness. Otolaryngol Head Neck Surg 149:753–758CrossRefPubMedGoogle Scholar
  18. 18.
    Lim HJ, Kim YT, Choi SJ, Lee JB, Park HY, Park K, Choung YH (2013) Efficacy of 3 different steroid treatments for sudden sensorineural hearing loss: a prospective, randomized trial. Otolaryngol Head Neck Surg 148:121–127CrossRefPubMedGoogle Scholar
  19. 19.
    Chou YF, Chen PR, Kuo IJ, Yu SH, Wen YH, Wu HP (2013) Comparison of intermittent intratympanic steroid injection and near-continual transtympanic steroid perfusion as salvage treatments for sudden sensorineural hearing loss. Laryngoscope 123:2264–2269CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Hideaki Suzuki
    • 1
    Email author
  • Hiroki Koizumi
    • 1
  • Jun-ichi Ohkubo
    • 1
  • Nobusuke Hohchi
    • 1
  • Shoji Ikezaki
    • 1
  • Takuro Kitamura
    • 1
  1. 1.Department of Otorhinolaryngology-Head and Neck Surgery, School of MedicineUniversity of Occupational and Environmental HealthKitakyushuJapan

Personalised recommendations